1.Raghavan R, Eknoyan G. Acute interstitial nephritis - a reappraisal and update. Clin Nephrol. 2014;82(3):149–162.
2.Praga M, Sevillano A, Aunon P, et al. Changes in the aetiology, clinical presentation and management of acute interstitial nephritis, an increasingly common cause of acute kidney injury. Nephrol Dial Transplant. 2015;30(9):1472–1479.
3.Clarkson MR, Giblin L, O’Connell FP, et al. Acute interstitial nephritis: clinical features and response to corticosteroid therapy. Nephrol Dial Transplant. 2004;19(11):2778–2783.
4.Michel DM, Kelly CJ. Acute interstitial nephritis. J Am Soc Nephrol. 1998;9(3):506–515.
5.Perazella MA, Markowitz GS. Drug-induced acute interstitial nephritis. Nat Rev Nephrol. 2010;6(8):461–470.
6.Schwarz A, Krause PH, Kunzendorf U, et al. The outcome of acute interstitial nephritis: risk factors for the transition from acute to chronic interstitial nephritis. Clin Nephrol. 2000;54(3):179–190.
7.Muriithi AK, Leung N, Valeri AM, et al. Biopsy-proven acute interstitial nephritis, 1993–2011: a case series. Am J Kidney Dis. 2014;64(4):558–566.
8.Muriithi AK, Leung N, Valeri AM, et al. Clinical characteristics, causes and outcomes of acute interstitial nephritis in the elderly. Kidney Int. 2015;87(2):458–464.
9.Perazella MA. Diagnosing drug-induced AIN in the hospitalized patient: a challenge for the clinician. Clin Nephrol. 2014;81(6):381–388.
10.Valluri A, Hetherington L, McQuarrie E, et al. Acute tubulointerstitial nephritis in Scotland. QJM. 2015;108(7):527–532.
11.Krishnan N, Perazella MA. Drug-induced acute interstitial nephritis: pathology, pathogenesis, and treatment. Iran J Kidney Dis. 2015;9(1):3–13.
12.Ulinski T, Sellier-Leclerc AL, Tudorache E, et al. Acute tubulointerstitial nephritis. Pediatr Nephrol. 2012;27(7):1051–1057.
13.Li C, Su T, Chu R, et al. Tubulointerstitial nephritis with uveitis in Chinese adults. Clin J Am Soc Nephrol. 2014;9(1):21–28.
14.Vila LM, Alarcon GS, McGwin G, Jr., et al. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXIX. Elevation of erythrocyte sedimentation rate is associated with disease activity and damage accrual. J Rheumatol. 2005;32(11):2150–2155.
15.Eudy AM, Vines AI, Dooley MA, et al. Elevated C-reactive protein and self-reported disease activity in systemic lupus erythematosus. Lupus. 2014;23(14):1460–1467.
16.Yang M, Ma N, Fu H, et al. Hematocrit Level could Reflect Inflammatory Response and Disease Activity in Patients with Systemic Lupus Erythematosus. Clin Lab. 2015;61(7):801–807.
17.Dima A, Opris D, Jurcut C, et al. Is there still a place for erythrocyte sedimentation rate and C-reactive protein in systemic lupus erythematosus? Lupus. 2016;25(11):1173–1179.
18.Nielung L, Christensen R, Danneskiold-Samsoe B, et al. Validity and Agreement between the 28-Joint Disease Activity Score Based on C-Reactive Protein and Erythrocyte Sedimentation Rate in Patients with Rheumatoid Arthritis. Arthritis. 2015;2015:401690.
19.Martire MV, Marino Claverie L, Duarte V, et al. Factors associated with sustained remission in patients with rheumatoid arthritis. Reumatol Clin. 2015;11(4):237–241.
20.Monach PA, Warner RL, Tomasson G, et al. Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis. Ann Rheum Dis. 2013;72(8):1342–1350.
21.Su T, Gu Y, Sun P, et al. Etiology and renal outcomes of acute tubulointerstitial nephritis: a single-center prospective cohort study in China. Nephrol Dial Transplant. 2018;33(7):1180–1188.
22.Wu Y, Yang L, Su T, et al. Pathological significance of a panel of urinary biomarkers in patients with drug-induced tubulointerstitial nephritis. Clin J Am Soc Nephrol. 2010;5(11):1954–1959.
23.Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group: KDIGO clinical practice guideline for acute kidney injury. Kidney International 2012;2:138.
24.Chawla LS, Bellomo R, Bihorac A, et al. Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nat Rev Nephrol. 2017;13(4):241–257.
25.Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008;8(4):753–760.
26.Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int. 1999;55(2):713–723.
27.Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612.
28.Simpson IJ, Marshall MR, Pilmore H, et al. Proton pump inhibitors and acute interstitial nephritis: report and analysis of 15 cases. Nephrology (Carlton). 2006;11(5):381–385.
29.Gonzalez E, Gutierrez E, Galeano C, et al. Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int. 2008;73(8):940–946.
30.Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol. 2013;13(3):159–175.
31.Masuzawa N, Nishimura A, Mihara Y, et al. Clinicopathological analysis of ANCA-associated glomerulonephritis focusing on plasma cell infiltrate. Clinical and experimental nephrology. 2019;23(12):1373–1381.